Home » Newsletters » BioWorld Science

BioWorld Science

July 25, 2007

View Archived Issues

Almirall acquires Hermal skincare business from Reckitt Benckiser

Profectus receives grant to develop anti-HIV antibodies

Taxus Element Stent begins new program

New antiinfective drugs disclosed in recent patent literature

New treatment options for neurological diseases claimed in recent patents

EpiCept NP-1 enters phase IIb and phase III studies for multiple indications

Schering-Plough announces acadesine licensing for cardiac surgery complications

Forbes Medi-Tech on track for corporate objectives and revenue growth

GW Pharmaceuticals's E.U. regulatory withdrawal

Meda enters U.S. market through strategic acquisition of MedPointe

Elan and Biogen Idec will appeal ruling on European application for natalizumab

FDA allows IND for Cougar Biotechnology's noscapine

Results from Samaritan's phase IIb study of novel HIV entry inhibitor

Tercica completes clinical trial enrollment for Increlex in pediatric primary IGFD

Phase I study to examine the safety and anticancer efficacy of the novel TCR/IL-2 fusion protein

Sygnis' phase IIa study of AX-200 for stroke completed

Ark withdraws EMEA early marketing approval application of Cerepro

FDA accepts QLT's labeling sNDA for Aczone

FDA grants permission to Kinex to proceed to phase I trials of KX2-391

Novel HCV NS5B polymerase inhibitors emerge from Pfizer R&D

Advisory committee recommendation for Evista in breast cancer risk reduction

Preliminary clinical safety of the recombinant gag-env HIV-1 protein-based vaccine VICHREPOL shown

Wyeth receives approvable letter for Pristiq in menopause-related vasomotor symptoms

CCR5 antagonist INCB-009471 exerts potent, prolonged antiretroviral activity in HIV patients

PF-429242: Example of novel S1P inhibitors for dyslipidemia and related disorders

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...